Compare Amphastar Pharmaceuticals Inc (AMPH) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ING Groep NV — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while ING Groep NV trades at $32.15 (market cap $92.53B). The key difference: ING Groep NV is far larger — about 112× Amphastar Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.91% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ING | |
|---|---|---|
Market Cap | $826.08M | $92.53B |
Sector | Health | Financials |
52-Week High | $30.81 | $32.96 |
52-Week Low | $16.87 | $22.45 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
ING trades at $32.39, down 0.34% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 27.84% net income margin and has beaten earnings expectations for three consecutive quarters. Recent developments include the launch of a global subscription banking model and a $0.88 dividend payment scheduled for May 2026.
The stock presents a compelling value opportunity with a P/E of 12.99 and strong analyst support (62.5% buy ratings). However, negative operating cash flow trends and exposure to European banking sector volatility represent key risks. Upside potential exists from continued earnings outperformance and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
